ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of “Hold” by Analysts

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) have earned a consensus recommendation of “Hold” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $28.25.

Several equities analysts have weighed in on the company. Northland Securities began coverage on ARS Pharmaceuticals in a research note on Thursday. They issued an “outperform” rating and a $25.00 price objective on the stock. Zacks Research upgraded ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Leerink Partners set a $26.00 price objective on ARS Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st.

ARS Pharmaceuticals Stock Down 0.6%

SPRY traded down $0.05 during trading on Thursday, reaching $8.14. 241,960 shares of the stock traded hands, compared to its average volume of 1,461,906. The stock has a market cap of $808.30 million, a price-to-earnings ratio of -4.67 and a beta of 0.86. ARS Pharmaceuticals has a fifty-two week low of $6.66 and a fifty-two week high of $18.90. The company has a debt-to-equity ratio of 1.47, a current ratio of 7.28 and a quick ratio of 7.06. The stock’s 50-day simple moving average is $8.90 and its two-hundred day simple moving average is $9.63.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.42). ARS Pharmaceuticals had a negative return on equity of 100.29% and a negative net margin of 203.25%.The firm had revenue of $28.09 million during the quarter, compared to analysts’ expectations of $25.58 million. As a group, equities research analysts expect that ARS Pharmaceuticals will post -0.55 EPS for the current year.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in SPRY. CWM LLC boosted its holdings in ARS Pharmaceuticals by 243.7% during the third quarter. CWM LLC now owns 2,547 shares of the company’s stock valued at $26,000 after purchasing an additional 1,806 shares in the last quarter. Torren Management LLC acquired a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in ARS Pharmaceuticals by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock valued at $56,000 after purchasing an additional 982 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $65,000. Finally, Russell Investments Group Ltd. boosted its holdings in ARS Pharmaceuticals by 197.5% during the third quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after purchasing an additional 4,427 shares in the last quarter. 68.16% of the stock is owned by institutional investors and hedge funds.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.